HERON THERAPEUTICS, INC. /DE/
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
HRTX$0.37+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net product sales | $34,711 | $38,903 |
| Cost of product sales | 10,638 | 8,457 |
| Gross profit | 24,073 | 30,446 |
| Operating expenses: | ||
| Research and development | 2,385 | 2,279 |
| General and administrative | 12,145 | 12,702 |
| Sales and marketing | 14,308 | 12,311 |
| Total operating expenses | 28,838 | 27,292 |
| (Loss) income from operations | (4,765) | 3,154 |
| Other expense, net | (3,346) | (519) |
| Net (loss) income | (8,111) | 2,635 |
| Other comprehensive (loss) income: | ||
| Unrealized loss on short-term investments | (10) | (12) |
| Comprehensive (loss) income | $(8,121) | $2,623 |
| Basic net (loss) income per share | $(0.04) | $0.02 |
| Diluted net (loss) income per share | $(0.04) | $0.01 |
| Weighted average common shares outstanding, basic | 189,646 | 153,490 |
| Weighted average common shares outstanding, diluted | 189,646 | 196,921 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.